Realtime | Geld | Brief | Zeit |
---|---|---|---|
32,750 | 33,750 | 03.05. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 41 | PR Newswire | WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen | |
25.04. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
19.04. | Spyre Therapeutics files to sell 33.36M shares of common stock for holders | 1 | Seeking Alpha | ||
18.03. | Spyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-Market | 2 | RTTNews | ||
18.03. | Spyre Therapeutics climbs 5%, prices $180M private financing | 2 | Seeking Alpha | ||
18.03. | Spyre Therapeutics secures $180 million in PIPE deal | 1 | Investing.com | ||
18.03. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.03. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
08.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 08.03.2024 | 297 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.03.2024
Aktien
1 US12738K1097 Cadeler A/S ADR
2 US3793786076... ► Artikel lesen | |
04.03. | Spyre Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
01.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 299 | PR Newswire | WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen | |
01.03. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
01.03. | Spyre Therapeutics, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
01.03. | Spyre Therapeutics GAAP EPS of -$4.05 | 1 | Seeking Alpha | ||
29.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
29.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.02. | Spyre Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
29.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 162 | PR Newswire | Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE"
SPY001, an anti-a4ß7 antibody... ► Artikel lesen | |
05.02. | Spyre Therapeutics appoints Mark C. Mckenna to its Board | 1 | Seeking Alpha | ||
05.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,760 | -1,36 % | Evotec, Vidac Pharma, BioNTech - das Milliardenrennen um die Krebstherapie | Die Onkologie steht an der Schwelle zu einer goldenen Ära. Getrieben von einer Zunahme der Krebserkrankungen und beeindruckenden wissenschaftlichen Fortschritten, darunter Gen- und Immuntherapien, eröffnet... ► Artikel lesen | |
VALNEVA | 3,482 | -0,51 % | Absturz bei Valneva! | Nichts zu feiern gibt es heute für Valneva-Aktionäre. Das Kurstableau weist nämlich ein Minus von rund vier Prozent aus. Mittlerweile kosten die Papiere nur noch 7,24 USD. Ist das nur ein kurzzeitiger... ► Artikel lesen | |
CORE ONE LABS | 0,142 | +3,65 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
MAINZ BIOMED | 0,709 | +1,72 % | BRISANTE Meldung setzt Mainz Biomed Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
TREVENA | 0,375 | +2,04 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
BLUEBIRD BIO | 0,841 | +0,65 % | bluebird bio, Inc. - 8-K, Current Report | ||
GALAPAGOS NV | 26,820 | -1,18 % | Galapagos NV: Galapagos reports first quarter 2024 financial results | Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 3,200 | +0,63 % | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 1,610 | -2,13 % | CTMX, HSDT and SNSE are among premarket gainers | ||
COHERUS | 2,106 | +0,05 % | Coherus BioSciences, Inc.: Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 | ||
CHIMERIX | 0,868 | -2,36 % | Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript | ||
CYTOMX THERAPEUTICS | 4,158 | +0,82 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
AYALA PHARMACEUTICALS | 0,465 | +2,20 % | Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced... ► Artikel lesen | |
ARCA BIOPHARMA | 3,000 | 0,00 % | ARCA biopharma, Inc.: ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update | ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:... ► Artikel lesen |